<DOC>
	<DOCNO>NCT02892409</DOCNO>
	<brief_summary>To evaluate safety , tolerability , pharmacokinetics ( PK ) quadruple therapy bismuth , clarithromycin , amoxicillin , TAK-438 versus quadruple therapy bismuth , clarithromycin , amoxicillin , lansoprazole .</brief_summary>
	<brief_title>TAK-438 Bismuth Drug Interaction Study</brief_title>
	<detailed_description>This phase 1 , double-blind , parallel group study subject Helicobacter pylorus ( HP positive ) , additionally , cytochrome P-450 ( CYP ) 2C19 extensive metabolizers ( EM ) evaluate safety , tolerability pharmacokinetics ( PK ) quadruple therapy bismuth , clarithromycin , amoxicillin , TAK-438 versus quadruple therapy bismuth , clarithromycin , amoxicillin , lansoprazole . The study enroll 30 participant . The treatment phase consist quadruple therapy twice daily ( BID ) tripotassium bismuth dicitrate ( 600 mg ) , clarithromycin ( 500 mg ) , amoxicillin ( 1000 mg ) , TAK-438 ( 20 mg ) ( Group B ) quadruple therapy BID tripotassium bismuth dicitrate ( 600 mg ) , clarithromycin ( 500 mg ) , amoxicillin ( 1000 mg ) , lansoprazole ( 30 mg ) ( Group A ) Days 1 14 . Subjects discharge Day 15 final PK blood sample collect procedure perform . This single-center conducted Korea . Participants remain confined study site check-in ( Day -1 ) Day 15 follow call Day 17 return Day 42 follow-up assessment .</detailed_description>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>1 . HP positive participant . 2 . Has body mass index great ( &gt; ) 18 less equal ( &lt; = ) 30 kilogram per square meter ( kg/m^2 ) weigh great equal ( &gt; = ) 50 kilogram ( kg ) . 3 . Is willing abstain strenuous exercise 72 hour first dose ( Day 1 ) Followup call Day 17 . 1 . Has positive urine drug result drug abuse Screening Checkin ( Day 1 ) . 2 . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define regular consumption 21 unit unit per week ) time prior Screening Visit unwilling agree abstain alcohol drug throughout study ( Day 17 ) . 3 . Has history gastroesophageal reflux disease ( GERD ) , symptomatic GERD , erosive esophagitis , duodenal ulcer , gastric ulcer , Barrett 's esophagus , ZollingerEllison syndrome . 4 . Has undergone therapeutic upper gastrointestinal endoscopic therapy ( example , endoscopic hemostasis excision include biopsy ) within 30 day prior Screening . 5 . Has undergone major surgical procedure within past 1 month schedule undergo surgical procedure may affect gastric acid secretion ( example , abdominal surgery , vagotomy , craniotomy ) . 6 . Has history cancer , except basal cell carcinoma Stage 1 squamous cell carcinoma skin remission least 5 year prior Day 1 . 7 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody/antigen Screening . 8 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 6 week prior Checkin . Cotinine test positive Screening Checkin . 9 . Has poor peripheral venous access . Has donate lose 450 milliliter ( mL ) blood volume ( include plasmapheresis ) , transfusion blood product within 90 day prior Day 1 . 10 . Has abnormal Screening Checkin laboratory value suggest clinically significant underlying disease subject follow laboratory abnormality : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) total bilirubin great ( &gt; ) upper limit normal ( ULN ) . 11 . Has reduce renal function assess estimate glomerular filtration rate &lt; 90 milliliter per min per 1.73 square meter ( mL/min/1.73 m^2 ) ( estimate Chronic Kidney DiseaseEpidemology Collaboration ) Screening Checkin .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>